BioCentury
ARTICLE | Emerging Company Profile

Eos: Reading the pathogenic cell

October 18, 1999 7:00 AM UTC

Many genomics companies are focused on a technology platform to generate various forms of data for clients, and not on developing therapeutics for their own account. But Eos Biotechnology Inc. is combining biological systems with its genomics and bioinformatics technologies to develop immunotherapeutics to treat cancer, cardiovascular and autoimmune disorders.

Through the marriage of these approaches, Eos hopes to identify key pathogenic cells involved in a given indication so that they may be targeted with immunotherapeutics, such as an antibody. ...